Semaglutide Associated with Central Serous Chorioretinopathy: A Case Report

Article Sidebar

PDF PDF (Português (Brasil))
Published: Jun 11, 2025
DOI: https://doi.org/10.52600/2763-583X.bjcr.2025.5.1.bjcr93
Keywords:
Obesity, Semaglutide, Central Serous Chorioretinopathy

Main Article Content

Lívia Peregrino Rodrigues
School of Medicine, University of Marília (UNIMAR)
https://orcid.org/0009-0003-8291-9722
André Lucas Loureiro Rubatino
Faculty of Medical Sciences of Belo Horizonte
Antônio Carmo Rubatino Junior
Unimed Conselheiro Lafaiete Medical Work Cooperative
https://orcid.org/0009-0000-1030-2975
Juliano Flávio Rubatino Rodrigues
School of Medicine of São José do Rio Preto (FAMERP)
https://orcid.org/0000-0002-7820-9811
Fernando Victor Martins Rubatino
Presidente Antônio Carlos University (UNIPAC)
https://orcid.org/0000-0001-8113-5342
Gerardo Maria de Araújo Filho
School of Medicine of São José do Rio Preto (FAMERP)
https://orcid.org/0000-0001-7112-8456

Abstract

This clinical case examines central retinal serous chorioretinopathy in a patient undergoing treatment with semaglutide. The subject of the case is a middle-aged male who developed this retinal condition following the administration of 14 mg of oral semaglutide. He reported a variety of vision-related disturbances that significantly impacted his daily activities. Fortunately, the visual impairments were completely resolved upon discontinuation of the medication. This case underscores the critical importance of vigilant ophthalmological monitoring for patients receiving semaglutide. It is imperative to monitor for any potential adverse effects on vision, thereby facilitating the prompt recognition and management of any changes or complications. By prioritizing regular eye examinations, healthcare providers can protect patients' visual health and promptly address any issues that may arise during their treatment.

Article Details

How to Cite
Rodrigues, L. P., Rubatino, A. L. L., Rubatino Junior, A. C., Rodrigues, J. F. R., Rubatino, F. V. M., & Araújo Filho, G. M. de. (2025). Semaglutide Associated with Central Serous Chorioretinopathy: A Case Report. Brazilian Journal of Case Reports, 5(1), bjcr93. https://doi.org/10.52600/2763-583X.bjcr.2025.5.1.bjcr93
Issue
Vol. 5 No. 1 (2025): January/December - 2025
Section
Clinical Case Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Lívia Peregrino Rodrigues, School of Medicine, University of Marília (UNIMAR)

School of Medicine, University of Marília (UNIMAR), Marília, São Paulo, Brazil.

André Lucas Loureiro Rubatino, Faculty of Medical Sciences of Belo Horizonte

Faculty of Medical Sciences of Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil.

Antônio Carmo Rubatino Junior, Unimed Conselheiro Lafaiete Medical Work Cooperative

Unimed Conselheiro Lafaiete Medical Work Cooperative, Conselheiro Lafaiete, Minas Gerais, Brazil.

Juliano Flávio Rubatino Rodrigues, School of Medicine of São José do Rio Preto (FAMERP)

School of Medicine of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, Brazil.

School of Medicine of Marília (FAMEMA), Marília, São Paulo, Brazil.

Unimed Bauru, Bauru, São Paulo, Brazil.

Fernando Victor Martins Rubatino, Presidente Antônio Carlos University (UNIPAC)

Presidente Antônio Carlos University (UNIPAC), Belo Horizonte, Minas Gerais, Brazil.

Gerardo Maria de Araújo Filho, School of Medicine of São José do Rio Preto (FAMERP)

School of Medicine of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, Brazil.

References

Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7):S177-85.

Brazil. Overweight and obesity as public health problems [Article in Portuguese: Sobrepeso e obesidade como problemas de saúde pública]. Brasília (BR): Ministério da Saúde; 2022.

Nilson EAF, Rezende LFM, Camargo JM. Incident cases and deaths attributable to overweight and obesity in Brazil until 2044. Presented at: International Congress on Obesity; 2024; São Paulo, Brazil.

Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO). Brazilian obesity guidelines 2016 [Article in Portuguese: Diretrizes brasileiras de obesidade 2016]. São Paulo (BR): ABESO; 2016. p. 188.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal L, Lingvay I, et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

Gazarini L. Semaglutide is approved by ANVISA for the control of obesity [Article in Portuguese: Semaglutida é aprovada pela ANVISA para controle da obesidade]. 2023 [cited 2024 Dec 8]. Available from: https://falandofarmacologia.ufms.br/semaglutida-e-aprovada-pela-anvisa-para-o-controle-da-obesidade/.

Berkovi MC, Strollo F. Semaglutide-eye-catching results. World J Diabetes. 2023;14(4):424-34.

Choi RH, Kang JY, Yoon G, et al. Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle. bioRxiv [Preprint]. 2024:623431.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72.

American Academy of Ophthalmology, North American Neuro-Ophthalmology Society. American Academy of Ophthal-mology and North American Neuro-Ophthalmology Society issue advice on weight loss drug and eye health. 2024 [cited 2024 Dec 10]. Available from: https://www.aao.org/newsroom/news-releases/detail/weight-loss-drug-and-eye-health.

Bracha P, Gubitosi R, Hu M, et al. Reversible bilateral central scotoma under scotopic conditions associated with oral sema-glutide. Am J Ophthalmol Case Rep. 2024;36:102121.

Park JB, Lee JY, Kim JH, et al. Central serous chorioretinopathy: treatment. Taiwan J Ophthalmol. 2022;12:394-408.

Ferrier C. Can semaglutide cause retinopathy? A comprehensive guide. BMI Doctors. 2024.

Kanda P, Silva R, Almeida F, et al. Pathophysiology of central serous chorioretinopathy. Eye (Lond). 2022;36:941-62.

Nussbaumer M, Gasser T, Riva CE, Schmidl D, Garhofer G, Polak K, et al. Effects of acute bouts of endurance exercise on retinal vessel diameters are age and intensity dependent. Age (Dordr). 2014;36(3):9650.

Mostafa NS, El Shereif RN, Manzour AF. Neglected cause of retinal detachment: a hospital-based case-control study on oc-cupational heavy lifting as a risk factor. J Egypt Public Health Assoc. 2021;96(1):31.

Zhang Q, Wang Y, Liu H, et al. Effects and potential mechanisms of exercise and physical activity on eye health and ocular diseases. Front Med (Lausanne). 2024;11:1353624.